•
OB
OBIO
Orchestra BioMed Holdings, Inc. Ordinary Shares
yahooSURGICAL & MEDICAL INSTRUMENTS & APPARATUS
--
Price Chart
Market Cap
230.94M
Volume
640.00
52W High
$6.16
52W Low
$2.20
Open
$0.00
Prev Close
$4.04
Day Range
0.00 - 0.00
About Orchestra BioMed Holdings, Inc. Ordinary Shares
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
Latest News
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
GlobeNewswire Inc.•Oct 27
Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
GlobeNewswire Inc.•Sep 4
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
GlobeNewswire Inc.•Aug 8
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
GlobeNewswire Inc.•Apr 23
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference
GlobeNewswire Inc.•Feb 12
Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors
GlobeNewswire Inc.•Feb 5
Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar?
Zacks Investment Research•Jun 24
All You Need to Know About Orchestra BioMed Holdings, Inc. (OBIO) Rating Upgrade to Buy
Zacks Investment Research•Jun 3